Mark Fridlyand - Director, Strategy & Corporate Development

Network quantification of EGFR signaling unveils potential for targeted combination therapy

Personalised medicine for the European Citizen

Edward Shenderovich - Co-founder & CEO at Synonym Biotechnologies

TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

Applications of comprehensive cancer progression models in the fight against cancer (Part 6) - Systems Biology of Cancer

Mark Fridlyand - Director, Strategy & Corporate Finance at Synonym Biotechnologies

PDF) Development strategies of sea bass enterprises in Mediterranean region of Turkey

Alex Fridlyand email address & phone number Newlight Partners Partner contact information - RocketReach

Coronavirus: Nowhere to go for Migrants in Rural MP